Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NGM:GTAB B vs VRTX, REGN, RVMD: FCF Margin % Comparison
For the Biotechnology subindustry, Glycorex Transplantation AB's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Glycorex Transplantation AB FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Glycorex Transplantation AB's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Glycorex Transplantation AB's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Glycorex Transplantation AB (NGM:GTAB B) has a FCF Margin % of -11.57% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Glycorex Transplantation AB and its competitors. According to the industry distribution chart, Glycorex Transplantation AB ranks #242 out of 953 companies in the Biotechnology industry, placing it in the top 25.4%.
Is Glycorex Transplantation AB's FCF Margin % too high?
Glycorex Transplantation AB's current FCF Margin % is -11.57%. Based on the distribution chart, Glycorex Transplantation AB ranks #242 out of 953 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Glycorex Transplantation AB has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Glycorex Transplantation AB's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Glycorex Transplantation AB ranks #242 out of 953 companies for FCF Margin %. This puts Glycorex Transplantation AB in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Glycorex Transplantation AB and its competitors. Glycorex Transplantation AB's current FCF Margin % is -11.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glycorex Transplantation AB stock overvalued right now?
Based on GuruFocus' analysis, Glycorex Transplantation AB (NGM:GTAB B) is currently considered Modestly Undervalued. The stock's GF Value™ is kr1.81, compared to a current price of kr1.46 — trading 19.3% below its estimated fair value. The current FCF Margin % is -11.57%. Glycorex Transplantation AB's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Glycorex Transplantation AB (NGM:GTAB B), the current FCF Margin % is -11.57% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Glycorex Transplantation AB (NGM:GTAB B) Overvalued in 2026?
Based on GuruFocus' analysis, Glycorex Transplantation AB stock appears to be undervalued.
The current stock price of kr1.46 is trading 19.3% below its estimated GF Value™ of kr1.81.
GuruFocus considers Glycorex Transplantation AB to be Modestly Undervalued.
Key valuation signals for NGM:GTAB B:
FCF Margin %: -11.57%
GF Value™: kr1.81 vs. price of kr1.46 (19.3% below fair value)
No single metric tells the full story. See the NGM:GTAB B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Glycorex Transplantation AB is a medical technology company. Its main product Glycosorb ABO is used clinically in six continents to facilitate blood group incompatible transplants, especially in kidney transplants from related living donors, but also in transplantation of liver, heart, lung and stem cells. Glycosorb ABO enables grafts regardless of the blood group of donors and recipients. The product is used in extracorporeal blood treatment, that is, a blood treatment that takes place outside the body in the same way as dialysis. Its segment is research, develop, manufacture, market and sell products in the field of organ transplantation or related areas. Geographically it operates in Europe, Australia, Singapore, India, and Other countries with majority of revenue from Europe.
61GF Score
Get the complete analysis for NGM:GTAB B
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NGM:GTAB B has been successfully added to your 
